332 related articles for article (PubMed ID: 8203786)
1. Controlled studies of Daflon 500 mg in chronic venous insufficiency.
Geroulakos G; Nicolaides AN
Angiology; 1994 Jun; 45(6 Pt 2):549-53. PubMed ID: 8203786
[TBL] [Abstract][Full Text] [Related]
2. Advantage of a micronized flavonoidic fraction (Daflon 500 mg) in comparison with a nonmicronized diosmin.
Amato C
Angiology; 1994 Jun; 45(6 Pt 2):531-6. PubMed ID: 8203783
[TBL] [Abstract][Full Text] [Related]
3. Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg.
Tsouderos Y
Int Angiol; 1989; 8(4 Suppl):53-9. PubMed ID: 2698902
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the clinical pharmacological activity of a phlebotonic agent. Application to the study of Daflon 500 mg.
Duchene Marullaz P; Amiel M; Barbe R
Int Angiol; 1988; 7(2 Suppl):25-32. PubMed ID: 3053940
[TBL] [Abstract][Full Text] [Related]
5. Venous tone: are the phlebotonic properties predictive of a therapeutic benefit? A comprehensive view of our experience with Daflon 500 mg.
Tsouderos Y
Z Kardiol; 1991; 80 Suppl 7():95-101. PubMed ID: 1792820
[TBL] [Abstract][Full Text] [Related]
6. Flavonoids. A review of the pharmacology and therapeutic efficacy of Daflon 500 mg in patients with chronic venous insufficiency and related disorders.
Struckmann JR; Nicolaides AN
Angiology; 1994 Jun; 45(6):419-28. PubMed ID: 8203767
[TBL] [Abstract][Full Text] [Related]
7. Double blind study of the pharmacodynamic and clinical activities of 5682 SE in venous insufficiency. Advantages of the new micronized form.
Cospite M; Dominici A
Int Angiol; 1989; 8(4 Suppl):61-5. PubMed ID: 2698903
[TBL] [Abstract][Full Text] [Related]
8. [Edema as a measure for severity of chronic venous insufficiency and efficacy of its treatment].
Sapelkin SV
Angiol Sosud Khir; 2008; 14(3):79-81. PubMed ID: 19791434
[TBL] [Abstract][Full Text] [Related]
9. [The drug therapy of chronic venous insufficiency (a trial of the clinical use of the preparation Detralex)].
Iablokov EG; Bogachev VIu; Domoradskaia AI
Ter Arkh; 1996; 68(10):80-1. PubMed ID: 9026954
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg.
Laurent R; Gilly R; Frileux C
Int Angiol; 1988; 7(2 Suppl):39-43. PubMed ID: 3053942
[TBL] [Abstract][Full Text] [Related]
11. At the crossroads of venous insufficiency and hemorrhoidal disease: Daflon 500 mg--repercussions of venous insufficiency on everyday life.
Launois R
Angiology; 1994 Jun; 45(6 Pt 2):495-504. PubMed ID: 8203779
[TBL] [Abstract][Full Text] [Related]
12. Laser Doppler and transcutaneous oximetry: modern investigations to assess drug efficacy in chronic venous insufficiency.
Belcaro G; Cesarone MR; de Sanctis MT; Incandela L; Laurora G; Février B; Wargon C; De Gregoris P
Int J Microcirc Clin Exp; 1995; 15 Suppl 1():45-9. PubMed ID: 8748889
[TBL] [Abstract][Full Text] [Related]
13. Clinical and hemodynamic outcomes in patients with chronic venous insufficiency after oral micronized flavonoid therapy.
Ting AC; Cheng SW; Wu LL; Cheung GC
Vasc Surg; 2001; 35(6):443-7. PubMed ID: 16222383
[TBL] [Abstract][Full Text] [Related]
14. Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence.
Cazaubon M; Benigni JP; Steinbruch M; Jabbour V; Gouhier-Kodas C
Vasc Health Risk Manag; 2021; 17():591-600. PubMed ID: 34556990
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefits of Daflon 500 mg in the most severe stages of chronic venous insufficiency.
Ramelet AA
Angiology; 2001 Aug; 52 Suppl 1():S49-56. PubMed ID: 11510597
[TBL] [Abstract][Full Text] [Related]
16. Techniques used to evaluate the cutaneous microcirculation: application of photoplethysmography to the assessment of a phlebotropic agent in the treatment of leg ulcers.
Guillot B
Angiology; 1994 Jun; 45(6 Pt 2):542-8. PubMed ID: 8203785
[TBL] [Abstract][Full Text] [Related]
17. At the Crossroads of Venous Insufficiency and Hemorrhoidal Disease: Daflon 500 mg. Proceedings of a symposium. Vienna, Austria, January 31, 1992.
Angiology; 1994 Jun; 45(6 Pt 2):493-584. PubMed ID: 7911285
[No Abstract] [Full Text] [Related]
18. From symptoms to leg edema: efficacy of Daflon 500 mg.
Nicolaides AN
Angiology; 2003; 54 Suppl 1():S33-44. PubMed ID: 12934755
[TBL] [Abstract][Full Text] [Related]
19. Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease.
Meyer OC
Angiology; 1994 Jun; 45(6 Pt 2):579-84. PubMed ID: 8203791
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of micronized purified flavonoid fraction: an overview.
Struckmann JR
J Vasc Res; 1999; 36 Suppl 1():37-41. PubMed ID: 10474049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
